title: Are there specific translational challenges in regenerative medicine? Lessons from other fields.
abstract: There is concern that translation 'from bench to bedside' within regenerative medicine (RM) will fail to materialize, or will be dismally slow, due to various challenges arising from the highly novel and disruptive nature of RM. In this article, we provide a summary of these challenges, and we critically engage with the notion that such challenges are specific to RM. It is important, we argue, not to overstate the exceptional nature of RM, as valuable lessons can be learned from elsewhere in medicine. Using several examples of technology adoption, we suggest that emerging RM products and procedures will have to work hard to find or create an adoption space if translation into the clinic is to be successful.
authors.affiliation: Science & Technology Studies Unit, Department of Sociology, University of York, Wentworth College, York, Y010 5DD, UK.
authors.forename: John
authors.initials: J
authors.lastname: Gardner
authors.affiliation: Sociology of Biomedicine & Healthcare Policy, Centre for Global Health Policy, University of Sussex, Brighton, BN1 9RH, UK.
authors.forename: Alex
authors.initials: A
authors.lastname: Faulkner
authors.affiliation: Centre for Global Health Policy, University of Sussex, Brighton, BN1 9RH, UK.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Mahalatchimy
authors.affiliation: Science & Technology Studies Unit, Department of Sociology, University of York, Wentworth College, York, Y010 5DD, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Webster
mesh_terms: D000818:Animals; D006801:Humans; D044968:Regenerative Medicine / Q000379:methods / Q000592:standards / Q000639:trends; D057170:Translational Research, Biomedical / Q000379:methods / Q000592:standards / Q000639:trends
keywords: adoption space; clinical trials; manufacturing; regulation; reimbursement; technology adoption; translational challenges; translational medicine